Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 3

Amendments to the Claims:

Please amend claims 25, 26, 34, 35, 43 and 44 as follows.

Please cancel claims 28-30, 36-39, 41, 42, 53 and 54 without prejudice.

PATENT

Attorney Docket No.: JHU1410-1

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-24 (Canceled)

- 25. (Currently Amended) A method for detecting the presence of a target myostatin variant nucleic acid sequence in a nucleic acid-containing specimen wherein the specimen is from a non-human bovine subject having increased muscle mass or having a predisposition for increased muscle mass as compared to a bovine subject having a wild-type nucleic acid sequence, said method comprising detecting the presence of the a target Piedmontese myostatin variant nucleotide sequence having a homozygous G1056A substitution, wherein the presence of the variant target nucleotide sequence is indicative of [[a]] increased muscle mass or a predisposition for increased muscle mass.
- 26. (Currently Amended) The method of claim 25, further comprising amplifying the <u>target variant</u> nucleic acid prior to detecting.
- 27. (Original) The method of claim 26, wherein the amplification is by means of oligonucleotides which hybridize to flanking regions of the target nucleic acid.

Claims 28-30 (Canceled)

- 31. (Original) The method of claim 27, wherein the nucleotide sequence of the flanking regions to which the oligonucleotides hybridize is:
 - 5'GATCCCAAAACACTCTCCTACCTCGGATCCGCG-3' (SEQ ID NO:1); and
 - 5'-CCCCTCAACAATTTTGAAACTGTGGGATCCGCG-3' (SEQ ID NO:2).

Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 4

32. (Original) The method of claim 31, wherein the oligonucleotides are:

5'-CGCGGATCCGAGGTAGGAGAGTGTTTTTGGGATC-3' (SEQ ID NO:3);

PATENT

Attorney Docket No.: JHU1410-1

and

5'-CGCGGATCCCACAGTTTCAAAATTGTTGAGGGG-3' (SEQ ID NO:4).

- 33. (Original) The method of claim 25, wherein the target nucleic acid is detected using a nucleic acid hybridization probe.
 - 34. (Currently Amended) The method of claim 33, wherein the target nucleic acid to which the nucleic acid hybridization probe hybridizes is selected from:

5'-GTGGAGTGTTCAT-3' (SEQ ID NO:5); and

5'-GATTCTGTCACAA-3' (SEQ ID NO:6); or

5'-AATTCACATTCTC-3' (SEQ ID NO:7); and

5'-AATTCATATTCTC-3' (SEQ ID NO:8).

35. (Currently Amended) The method of claim 33, wherein the nucleic acid hybridization probe is selected from:

5'-ATGAACACTCCAC-3' (SEQ ID NO:9); and

5'-TTGTGACAGAATC-3' (SEQ ID NO:10); or

5'-GAGAATGTGAATT-3' (SEQ ID NO:11); and

5'-GAGAATATGAATT-3' (SEQ ID NO:12), respectively.

Claims 36-39 (Canceled)

- 40. (Original) The method claim 25, wherein the specimen is a food product.
- 41. (Canceled)
- 42. (Canceled)

Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 5

43. (Currently Amended) A kit useful for the detection of a target nucleic acid sequence in a specimen from a subject having increased muscle mass as compared to a subject having a wild-type nucleic acid sequence or having a predisposition for increased muscle mass, wherein the presence of the target nucleic acid sequence in the specimen is indicative of having or predisposed to having increased muscle mass, the kit comprising one or more containers comprising a first container containing a nucleic acid hybridization probe, wherein the probe hybridizes to a target nucleic acid selected from:

PATENT

Attorney Docket No.: JHU1410-1

5'-GTGGAGTGTTCAT-3' (SEQ ID NO:5); and 5'-GATTCTGTCACAA-3' (SEQ ID NO:6); of 5'-AATTCACATTCTC-3' (SEQ ID NO:7); and

5'-AATTCATATTCTC-3' (SEQ ID NO:8); and

a second container containing a means for detecting hybridization of the probe with the target nucleic acid.

44. (Currently Amended) The kit of claim 43, wherein the nucleic acid hybridization probe is-selected from:

5'-ATGAACACTCCAC-3' (SEQ ID NO:9); and
5'-TTGTGACAGAATC-3' (SEQ ID NO:10); or
5'-GAGAATGTGAATT-3' (SEQ ID NO:11); and
5'-GAGAATATGAATT-3' (SEQ ID NO:12), respectively.

- 45. (Original) The kit of claim 43, further comprising an amplification polymerase and deoxyribonucleotide(s).
- 46. (Original) The kit of claim 43, wherein the detectable means is selected from the group consisting of enzymes, chemiluminescers, radionuclides, fluorescent compounds, heavy metals and ligands.
- 47. (Original) The kit of claim 43, further comprising a third container containing oligonucleotides which hybridize to the flanking regions of a target nucleic acid, wherein the oligonucleotides hybridize to a nucleic acid having a sequence of:

Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 6

5'-GATCCCAAAACACTCTCCTACCTCGGATCCGCG-3' (SEQ ID NO:1);

5'-CCCCTCAACAATTTTGAAACTGTGGGATCCGCG-3' (SEQ ID NO:2).

PATENT

Attorney Docket No.: JHU1410-1

48. (Original) The kit of claim 43, further comprising a third container containing oligonucleotides which hybridize to the flanking regions of a target nucleic acid, wherein the oligonucleotides are:

5'-CGCGGATCCGAGGTAGGAGAGTGTTTTGGGATC-3' (SEQ ID NO: 3); and

5'-CGCGGATCCCACAGTTTCAAAATTGTTGAGGGG-3' (SEQ ID NO: 4).

49. (Original) A kit useful for the detection of a target nucleic acid sequence in a specimen from a subject having increased muscle mass as compared to a subject having a wild-type nucleic acid sequence or having a predisposition for increased muscle mass, wherein the presence of the target nucleic acid sequence in the specimen is indicative of having or predisposed to having increased muscle mass, the kit comprising carrier means being compartmentalized to receive in close confinement therein one or more containers comprising a first container containing oligonucleotides which hybridize to the flanking regions of a target nucleic acid, wherein the oligonucleotides hybridize to a nucleic acid having a sequence of:

5'-GATCCCAAAAACACTCTCCTACCTCGGATCCGCG-3' (SEQ ID NO:1); 5'-CCCCTCAACAATTTTGAAACTGTGGGATCCGCG-3' (SEQ ID NO:2).

- 50. (Original) The kit of claim 45, wherein the oligonucleotides are:
- 5'-CGCGGATCCGAGGTAGGAGAGTGTTTTGGGATC-3' (SEQ ID NO:3); and
- 5'-CGCGGATCCCACAGTTTCAAAATTGTTGAGGGG-3' (SEQ ID NO:4).

Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 7

51. (Withdrawn) A kit useful for the detection of a variant myostatin polypeptide in a specimen from a subject having increased muscle mass as compared to a subject having a wild-type nucleic acid sequence or having a predisposition for increased muscle mass, the kit comprising one or more containers comprising a container containing an antibody which binds to amino acid residues 1-273 of wild-type myostatin polypeptide.

PATENT

Attorney Docket No.: JHU1410-1

- 52. (Withdrawn) A kit useful for the detection of a variant myostatin polypeptide in a specimen from a subject having increased muscle mass as compared to a subject having a wild-type nucleic acid sequence or having a predisposition for increased muscle mass, the kit comprising one or more containers comprising a container containing an antibody which binds to amino acid residues 274-375 of wild-type myostatin polypeptide.
 - 53. (Canceled)
 - 54. (Canceled)
 - 55. (Original) The method of claim 25, wherein the specimen is muscle tissue.
 - 56. (Original) The method of claim 55, wherein the tissue is skeletal muscle tissue.
- 57. (Withdrawn) A method for identifying a nucleotide sequence of a naturally occurring mutant of a gene which normally encodes a myostatin protein, of a mammal displaying muscular hyperplasia, the method comprising:

obtaining a sample of material containing DNA from the mammal; and contacting the sample with a nucleic acid probe based on a nucleotide sequence of a known gene encoding myostatin in order to identify the nucleotide sequence of the mutant gene.

- 58. (Withdrawn) The method of claim 57, wherein the probe binds to a nucleotide sequence identified as SEQ ID NO: 5, 6, 7 or 8.
- 59. (Withdrawn) The method of claim 58, wherein the probe is based on SEQ ID NO:11 or SEQ ID NO:12.

Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 8

60. (Withdrawn) The method of claim 59, wherein the probe is at least 10-50 nucleotides in length.

PATENT

Attorney Docket No.: JHU1410-1

- 61. (Withdrawn) The method of claim 57, wherein the step of probing the sample includes exposing the DNA to the probe under hybridizing conditions and further comprising isolating hybridized nucleic acid molecules.
- 62. (Withdrawn) The method of claim 61, further comprising the step of sequencing isolated DNA.
- 63. (Withdrawn) The method of claim 57, wherein the mammal is a bovine mammal and the probe is based on a said nucleotide sequence identified as GenBank Accession No. AFO19620.
- 64. (Withdrawn) The method of claim 62, further comprising the step of isolating and sequencing a cDNA or mRNA encoding the complete mutant myostatin protein.
- 65. (Withdrawn) The method of claim 64, further comprising the step of isolating and sequencing a functional wild type myostatin from a said mammal not displaying muscular hyperplasia.
- 66. (New) A method for detecting the presence of a target myostatin variant nucleic acid sequence in a nucleic acid-containing specimen wherein the specimen is from a bovine subject having increased muscle mass or having a predisposition for increased muscle mass as compared to a bovine subject having a wild-type nucleic acid sequence, said method comprising detecting the presence of a target Belgian Blue myostatin variant nucleotide sequence having a deletion of nucleotides 937-947, wherein the presence of the variant target nucleotide sequence is indicative of increased muscle mass or a predisposition for increased muscle mass.
- 67. (New) The method of claim 66, further comprising amplifying the target variant nucleic acid prior to detecting.

Lee and McPherron

Application No.: 10/662,003 Filed: September 11, 2003

Page 9

- 68. (New) The method of claim 67, wherein the amplification is by means of oligonucleotides which hybridize to flanking regions of the target nucleic acid.
- 69. (New) The method of claim 68, wherein the nucleotide sequence of the flanking regions to which the oligonucleotides hybridize is:

5'GATCCCAAAACACTCTCCTACCTCGGATCCGCG-3' (SEQ ID NO:1); and 5'-CCCCTCAACAATTTTGAAACTGTGGGATCCGCG-3' (SEQ ID NO:2).

70. (New) The method of claim 69, wherein the oligonucleotides are: 5'-CGCGGATCCGAGGTAGGAGAGTGTTTTGGGATC-3' (SEQ ID NO:3); and

5'-CGCGGATCCCACAGTTTCAAAATTGTTGAGGGG-3' (SEQ ID NO:4).

PATENT

Attorney Docket No.: JHU1410-1

- 71. (New) The method of claim 65, wherein the target nucleic acid is detected using a nucleic acid hybridization probe.
 - 72. (New) The method of claim 71, wherein the target nucleic acid to which the nucleic acid hybridization probe hybridizes is:

5'-GATTCTGTCACAA-3' (SEQ ID NO:6); or 5'-AATTCATATTCTC-3' (SEQ ID NO:8).

- 73. (New) The method of claim 71, wherein the nucleic acid hybridization probe is: 5'-TTGTGACAGAATC-3' (SEQ ID NO:10); or 5'-GAGAATATGAATT-3' (SEQ ID NO:12).
- 74. (New) The method of claim 65, wherein the specimen is muscle tissue.
- 75. (New) The method of claim 74, wherein the tissue is skeletal muscle tissue.